Benzodiazepine recognition site ligands and GABA_A receptors

Bibliography

• ROMER D, BUSCHER HH, HILL RC: An opioid benzodi-azepine. Nature (1982) 298:759–760.
   PubMed Web of Science ®Google Scholar
• WEBER KH, HEUER H: Structure-activity relationships and effects of platelet-activating factor antagonists in the hetrazepine series. Int. Arch. Allergy Appl. Immunol. (1989) 88:82–87.
   PubMedGoogle Scholar
• HERTZBERG RP, HECHT SM, REYNOLDS VL, MOLINEUXIJ, HURLEY LH: DNA sequence specificity of the pyrrolo[1,4]benzodiazepine antitumour antibiotics. Methidiumpropyl-EDTA-ironfiD footprinting analysis of DNA binding sites for anthramycin and related drugs. Biochemistry (1986) 25:1249–1258.
   Google Scholar
• BARKLEY MD, CHEATHAM S, THURSTON DE, HURLEYLH: Pyrrolo[1,4]benzodiazepine antitumour antibi-otics: evidence for two forms of tomaymycin bound to DNA. Biochemistry (1986) 25:3021–3031.
   PubMedGoogle Scholar
• SLADE J, STANTON JL, BEN-DAVID D, MAZZENGA GC:Angiotensin converting enzyme inhibitors: 1,5-benzothiazepine derivatives. J. Med. Chem. (1985) 28:1517–1521.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA H, BALZARINI J, PAUWELS R, SCHOLS D,DESMYTER J, DE CLERCQ E: Anti-HIV-1 activity of antiviral compounds, as quantitated by focal immuno-assay in CD4+ HeLa cells and a plaque assay in MT-4 cells. J. Vim]. Methods (1990) 29:197–208.
   PubMed Web of Science ®Google Scholar
• EVANS BE, BOCK MG, RITTLE KE et al.: Design of potent,orally effective, non-peptoidal antagonists of the peptide hormone cholecystokinin. Proc. Natl. Acad. Sci. (1986) 83:4918–4922.
   PubMed Web of Science ®Google Scholar
• DZIADULEWICZ EK, BROWN MC, DUNSTAN AR, LEE W,SAID NB, GARRATT PJ: The design of non-peptide human bradykinin B2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold. Bioorg. Med. Chem. Lett. (1999) 9:463–468.
   PubMedGoogle Scholar
• RIPKA WC, DE LUCA GV, BACH AC, POTTORF RS, BLANEYJM: Protein I3-turn mimetics. I. Design, synthesis, and evaluation in model cyclic peptides. Tetrahedron (1993) 49:3593–3608.
   Google Scholar
• STERNBACH L: The benzodiazepine story. J. Med. Chem.(1979) 22:1–7.
   PubMed Web of Science ®Google Scholar
• DOBLE A, MARTIN IL: The GABAA-benzodiazepine receptor as a target for psychoactive drugs. Landes RG, USA (1996):229–264.
   Google Scholar
• ••Monograph including preclinical and clinical studies to1995.
   Google Scholar
• WOODS JH, KATZ JL, WINGER G: Benzodiazepines: use, abuse and consequences. Pharmacol. Rev. (1992) 44:151–347.
   PubMed Web of Science ®Google Scholar
• ••Exhaustive review of the literature to 1992
   Google Scholar
• HINDMARCH I: Benzodiazepines: what is missing from the white list. Pharmacal. J. (1985) 234:506–507.
   Google Scholar
• WEINTRAUB M, SINGH S, BYRNE L et al.: New York State triplicate benzodiazepine regulations. JAMA (1991) 266:2392–2397.
   PubMed Web of Science ®Google Scholar
• HOLTON A, RILEY P, TYRER P: Factors predicting long-term outcome after chronic benzodiazepine therapy. J. Affect Dis. (1992) 24:245–252.
   PubMed Web of Science ®Google Scholar
• SCHWEIZER E, RICKELS K: Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr. Scand. Suppl. (1998) 393: 95–101.
   PubMedGoogle Scholar
• RUNDFELT C, WLAZ P, HONACK D, LOSCHER W: Anticonvulsant tolerance and withdrawal characteris-tics of benzodiazepine receptor ligands in different seizure models in mice. Comparison of diazepam, bretazenil and abecarnil. J. Pharmacol. Exp. Ther. (1995) 275:693–702.
   PubMedGoogle Scholar
• MAJEWSKA MD: Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog. Neurobiol. (1992) 38:379–395.
   Google Scholar
• NAYEEM N, GREEN TP, MARTIN IL, BARNARD EA: Quater-nary structure of the native GABAA receptor determined by electron microscopic image analysis. Neurochem. (1994) 62:815–818.
   PubMed Web of Science ®Google Scholar
• SIEGHART, W: Structure and pharmacology of y-aminobutyric acidA receptor subtypes. Pharmacol Rev. (1995) 47:182–234.
   Web of Science ®Google Scholar
• WISDEN W, LAURIE DJ, MONYER H et al.: The distribu-tion of 13 GABAA receptor subunit mRNAs in rat brain. I Telencephalon, diencephalon, mesencephalon. J. Neurosci. (1992) 12:1040–1062.
   PubMed Web of Science ®Google Scholar
• LAURIE DJ, SEEBURG PH, WISDEN W et al.: The distribu-tion of 13 GABAA receptor subunit mRNAs in rat brain. 2 Olfactory bulb and cerebellum. J. Neurosci. (1992) 12:1063–1076.
   Google Scholar
• WHITING PJ, MCKERNAN RM, WAFFORD KA: Structure and pharmacology of vertebrate GABAA receptor subtypes. Int. Rev. Neurobiol (1995) 38:95–137.
   PubMed Web of Science ®Google Scholar
• •Review of receptor subtype diversity.
   Google Scholar
• HAEFELY W, MARTIN JP, SCHOCH P: Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol. Set. (1990) 11:452–456.
   PubMed Web of Science ®Google Scholar
• FACKLAM M, SCHOCH P, BONETTI EP: Relationship between benzodiazepine receptor occupancy and functional effects of four ligands of differing intrinsic activities. J. Pharmacol Exp. Ther. (1992) 261:83–91.
   Google Scholar
• PETERSEN E, JENSEN LH, DREJER J, HONORE T: New perspectives in benzodiazepine pharmacology. Pharmacopsychiatly (1986) 19:4–6.
   Google Scholar
• BRODIE MJ: Status epilepticus in adults. Br. Med. J. (1990) 336:551–552.
   Google Scholar
• MARRIOTT S, TYRER P: Benzodiazepine dependence. Avoidance and withdrawal. Drug Saf (1993) 9:93–103.
   PubMed Web of Science ®Google Scholar
• HENINGER C, SAITO N, TALLMAN JF et al: Effects of chronic diazepam administration on GABAA receptor mRNAs in rat brain. J. Mol. Neurosci. (1990) 2:101–107.
   PubMedGoogle Scholar
• IMPAGNATIELLO F, PRESOLD C, LONGONE H et al: Modifications of y-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam. Mol. Pharmacol (1996) 49:822–831.
   PubMed Web of Science ®Google Scholar
• HOLT RA, BATESON AN, MARTIN IL: Chronic treatment with diazepam or abecarnil differentially affects the expression of GABAA receptor subunit mRNAs in rat cortex. Neuropharmacology (1996) 35:1457–1463.
   PubMedGoogle Scholar
• TENEN SS, HIRSCH JD: 13-carboline-3-carboxylic acid ethyl ester antagonises diazepam activity. Nature (1980) 288:609–610.
   PubMedGoogle Scholar
• COWAN P, GREEN AR, NUTT D, MARTIN IL: Ethyl-13-carboline-3-carboxylate lowers seizure threshold and antagonises flurazepam induced sedation in rats. Nature (1981) 290:54–55.
   PubMedGoogle Scholar
• POLC P, BONETTI EP, SCHAFFNER R, HAEFELY W: A three state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antago-nist Ro 15-1788, benzodiazepine tranquilizers, p-carbolines, and phenonbarbitone. Naunyn-Schmiedeberg's Arch. Pharmacol (1982) 321:260–264.
   Google Scholar
• VENAULT P, CHAPOUTHIER G, PRADO DE CARVALHO Let al.: Benzodiazepine impairs and p-carboline enhances performance and learning and memory tasks. Nature (1986) 321:864–866.
   Google Scholar
• DUKA T, STEPHENS DN, KRAUSE W, DOROW R: Studieson the benzodiazepine receptor antagonist ZK93426: preliminary observations on psychotropic activity. Psychopharmacology (1987) 93:421–427.
   PubMedGoogle Scholar
• DOROW R, HOROWSKI R, PASCHELKE G et al.: Severe anxiety induced by FG7142, a p-carboline ligand for benzodiazepine receptors. Lancet (1983) ii:98
   Google Scholar
• MOHLER H, OKADA T: Benzodiazepine receptor: demonstration in the central nervous system. Science (1977) 198:849–851.
   PubMed Web of Science ®Google Scholar
• THOMAS JW, TALLMAN JF: Characterization of photoaf-finity labeling of benzodiazepine binding sites. J. Biol. Chem. (1981) 256:9838–9842.
   PubMedGoogle Scholar
• THOMAS JW, TALLMAN JF: Photoaffinity labeling of benzodiazepine receptors causes altered agonist-antagonist interactions. J. NeuroscL (1983) 3:433–440.
   PubMed Web of Science ®Google Scholar
• MOHLER H, BURKHARD WP, KELLER HH, RICHARDS JG,HAEFELY W: Benzodiazepine antagonist Ro 15-1788: binding characteristics and interaction with drug-induced changes in dopamine turnover and cerebellar cGMP levels. J. Neurochem. (1981) 37:714–722.
   PubMed Web of Science ®Google Scholar
• MOHLER H, RICHARDS JG: Agonist and antagonist benzodiazepine receptor interaction in vitro. Nature (1981) 294:763–765.
   PubMed Web of Science ®Google Scholar
• HADINGHAM KL, HARKNESS PC, MCKERNAN RM et al.: Stable expression of mammalian type A gamma-aminobutyric acid receptors in mouse cells: demonstration of functional assembly of benzodi-azepine responsive sites. Proc. Natl. Acad. ScL USA (1992) 89:6378–6382.
   PubMed Web of Science ®Google Scholar
• •Cell lines for the inducible expression of receptor subtypes.
   Google Scholar
• FILE SE, PELLOW S: Behavioural pharmacology of minor tranquilizers. In: Psychotropic Drugs of Abuse. Balfour DJK (Ed.), Pergamon Press, UK (1990):147–172.
   Google Scholar
• LANGER SZ, ARBILLA S, TANS et al.: Selectivity for omega receptor subtypes as a strategy for the development of amdolytic drugs. Pharmacopsychiatly (1990) 23:103–107.
   PubMed Web of Science ®Google Scholar
• QUIRK K, BLURTON P, FLETCHER S et al: [3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the a5 subunit. Neuropharmacology (1996) 35:1331–1335.
   PubMed Web of Science ®Google Scholar
• MCNAMARA JO: Analysis of the molecular basis of kindling development. Psychiatry Clin. Neurosci. (1995) 49:S175–178.
   PubMed Web of Science ®Google Scholar
• KURIBARA H, STAVINOHA WB, MARUYAMA Y: Honokiol. A putative amdolytic agent extracted from magnolia bark, has not diazepam-like side-effects in mice. J. Pharm. Pharmacol (1999) 51:97–103.
   Google Scholar
• RICE DP, MILLER LS: Health economics and costimplications of anxiety and other mental disorders in the United States. Br. J. Psychiatr. Suppl. (1998) 34:4–9.
   PubMedGoogle Scholar
• JONES A, KORPI ER, MCKERNAN, RM et al.: Ligand gatedion channel subunit partnerships: GABAA receptor a6 subunit gene inactivation inhibits 8 subunit expres-sion. J. NeuroscL (1997) 17:1350–1362.
   PubMedGoogle Scholar